Top 5 articles on kidney cancer from 2021
The year 2021 has been a pivotal year for kidney cancer, with new treatments – like combination immunotherapy – dramatically changing the landscape and outcomes for patients with metastatic disease. In fact, Dr Eric Jonasch of the National Comprehensive Cancer Network said that Lenvima (lenvatinib) plus Keytruda (pembrolizumab) is “one of the most powerful regimens tested so far in this particular setting, in advanced kidney cancer. “.
Read about this breakthrough and more in CUREÂ®’s 5 Most Read Kidney Cancer Articles.
1. Combinations of immunotherapy offer âhope and promiseâ for patients with advanced renal cell carcinoma
In early 2021, pivotal results from the CLEAR phase 3 clinical trial were released, showing that Lenvima (lenvatinib) plus Keytruda (pembrolizumab) improved progression-free survival and overall survival and response rates in patients with advanced renal cell carcinoma (CRC).
2. Antiviral drugs that block cholesterol / hepatitis C may work on kidney cancer.
Some drugs that treat hepatitis C inhibit the SCARB1 protein, which research has shown may prevent clear-cell RCC cells from multiplying. Since these drugs already exist and are known to be mostly safe, researcher Celeste Simon calls it a “luck break”. However, research in this area is still in its early stages.
3. NCCN recommends Lenvima Plus Keytruda for first-line renal cell carcinoma: what patients need to know
The best CUREÂ® Kidney Cancer article of the year was about the improved results seen with Lenvima and Keytruda in selected kidney cancer patients. After seeing the results of the Phase 3 CLEAR trial, the National Comprehensive Cancer Network (NCCN) recommended that this regimen be used as the first-line treatment for advanced renal cell carcinoma. We spoke with someone from NCCN about what patients with the disease need to know about this decision.
4. Higher BMI may be associated with improved overall survival in patients with metastatic kidney cancer.
While being overweight or obese comes with its own set of health problems, research published in JAMA Oncology found that individuals with a high body mass index (BMI) and metastatic RCC treated with immunotherapy tended to have improved overall survival rates compared to those with a lower BMI. Researchers have dubbed this the âobesity paradoxâ.
5. Frequent active surveillance versus systemic therapy for metastatic renal cell carcinoma
Almost a third of patients with metastatic RCC undergo active surveillance instead of immediate treatment, and this may be a safe option for many patients – with savings in money and no treatment-related side effects – according to research published in the journal Cancer.
Stay up to date on the latest news and information on the CUREÂ® Kidney Cancer page.
For more information on cancer updates, research and education, be sure to subscribe to CUREÂ® newsletters here.